Abstract: The present invention provides a composition consisting of a monoclonal antibody that defines an epitope found on an antigen antigen/normal cross-reacting antigen produced by hybridoma XMMBR-B14 (HB 9308) conjugated to a detectable moiety, and a kit containing the antibody. Hybridoma XMMBR-B14 was deposited with the ATCC on Jan. 14, 1987 and given the ATCC Accession No. HB 9308.

Abstract: Methods for determining the prognosis of human carcinomas utilizing a marker specific for malignant cells of aggressive cancers. Cell lines have been produced that secrete monoclonal antibodies useful in detecting such markers, including a 51,000-dalton keratin protein, specific for myoepithelial cells, e.g., in tissue culture. Pharmaceutical compositions containing these antibodies, which can be in combination with cytotoxic agents and the use of such compositions in the management of carcinomas are included.Prior to filing of this patent application, the continuous transformed cell lines described herein was deposited in the American Type Culture Collection and designated Accession No. HB9288.

Abstract: An assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.

Abstract: The present invention provides a novel hybridoma cell line secreting monoclonal antibodies (MoAbs) that define an epitope found on an antigen of the classification termed CEA/NCA (carcinoembryonic antigen/normal cross-reacting antigen). The MoAbs of the invention find particular utility as the targeting moiety of immunotoxin and immunoimaging conjugates.Hybridoma XMMBR-B14 was deposited with the A.T.C.C. on Jan. 14, 1987 and given A.T.C.C. Accession No. HB 9308.

Abstract: As assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.